Pharma companies await clarity, eye a dose of stability in India-US deal
NEW DELHI: Drug makers are set to gain clarity under the proposed India-US trade agreement, sharpening expansion plans in the world’s most lucrative pharmaceutical market. While the sector was insulated from punitive US tariffs, the generics business of major companies, including Sun Pharma, Dr Reddy’s and Cipla faced significant headwinds in the third quarter ended…
